Health
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
RAHWAY, N.J. & NUTLEY, N.J., February 28, 2026--WELIREG Plus LENVIMA Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated RCC Patients
About this update from Eisai Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":217,"url":"https://media.zenfs.com/en/business-wire.com/390e3cccb6bfa2e856aef25e6202e630"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Y8f9Jp9vApZv3fLvq2_roQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQzNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/390e3cccb6bfa2e856aef25e6202e630","width":480,"height":217}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":324,"url":"https://media.zenfs.com/en/business-wire.com/6982ada5859ee9130a873dc9f952d434"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wJfIJLsChFwHFe2JRaG_Cw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6982ada5859ee9130a873dc9f952d434","width":480,"height":324}}},{"type":"text","content":"This is the first positive Phase 3 trial of a HIF-2 alpha inhibitor in combination with a multi-targeted tyrosine kinase inhibitor, the first for patients with RCC whose disease progressed on or after treatment with anti-PD-1/L1 therapy, and the first to improve PFS compared to a modern tyrosine kinase inhibitor","length":313,"tagName":"p","attribs":{}},{"type":"text","content":"Based on these data, the U.S. FDA has accepted for review two supplemental New Drug Applications for WELIREG plus LENVIMA in certain previously treated patients with advanced RCC","length":178,"tagName":"p","attribs":{}},{"type":"text","content":"RAHWAY, N.J. & NUTLEY, N.J., February 28, 2026--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced the first presentation of results from the Phase 3 LITESPARK-011 trial evaluating the dual oral regimen of WELIREG® (belzutifan), Merck’s first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, plus LENVIMA® (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of patients with advanced renal cell carcinoma (RCC) whose disease progressed on or after treatment with anti-programmed death receptor-1 (PD-1)/programmed death-ligand 1 (PD-L1) therapy. These data are being presented as a la...